Business Context and Reporting Period
Company: Eli Lilly and Company (LLY)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2025
Business Overview: Eli Lilly operates as a single reportable segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. The company reported record revenue and net income driven primarily by the cardiometabolic portfolio (Mounjaro and Zepbound).
Key Financial Metrics
| Metric ($ millions) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $17,600.8 | $11,439.1 | $45,887.0 | $31,509.9 |
| Net Income | $5,582.5 | $970.3 | $14,002.3 | $6,180.2 |
| Diluted EPS | $6.21 | $1.07 | $15.56 | $6.83 |
| Gross Margin % | 82.9% | 81.0% | 83.3% | 80.9% |
| Operating Cash Flow (9M) | $13,588.4 | $6,344.1 | - | - |
| Cash & Equivalents (Sep 30) | $9,791.9 | $3,268.4 | - | - |
| Total Debt (Sep 30) | $42,506.6 | $29,306.7 | - | - |
Note: Total debt includes short-term borrowings and current maturities of long-term debt ($1,633.0M) plus long-term debt ($40,873.6M).
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 54% in Q3 and 46% in the first nine months of 2025 compared to the prior year. Growth was driven by volume increases in Mounjaro and Zepbound, partially offset by lower realized prices.
- Profitability: Net income surged significantly (not meaningful percentage change for Q3 due to low prior year base; 127% increase for 9M). Gross margin percentage improved to 82.9% (Q3) and 83.3% (9M) due to favorable product mix.
- Expenses:
- R&D: Increased 27% (Q3) and 20% (9M) due to continued investment in the pipeline.
- Acquired IPR&D: Decreased significantly to $655.7M (Q3) and $2,381.2M (9M) compared to $2,826.4M and $3,091.2M in 2024, reflecting a shift in acquisition timing.
- Special Charges: Asset impairment and restructuring charges were $364.9M (Q3) and $399.9M (9M), primarily related to litigation and Verve acquisition integration costs.
- Balance Sheet: Cash and cash equivalents grew to $9.79 billion from $3.27 billion at year-end 2024. Total debt increased by $8.86 billion to $42.51 billion, funded by new debt issuances in February and August 2025 to support acquisitions and general business purposes.
Guidance, Outlook, and Risks
- Product Pipeline:
- Tirzepatide (Mounjaro/Zepbound): Supply currently exceeds demand in the U.S. Applications submitted for pediatric type 2 diabetes; Phase 3 cardiovascular outcomes trial met primary endpoint.
- Orforglipron: Phase 3 trials for obesity and type 2 diabetes met primary endpoints. New trials initiated for hypertension, osteoarthritis, and stress urinary incontinence.
- Other Approvals: Donanemab (Kisunla) approved in EU for Alzheimer's; Imlunestrant (Inluriyo) approved by FDA for breast cancer.
- Regulatory & Pricing Risks:
- OBBBA: The "One Big Beautiful Bill Act" enacted in July 2025 modified U.S. tax laws, resulting in a $350.3M tax expense charge in Q3 2025 and impacting effective tax rates.
- IRA Pricing: Jardiance was selected for government-set pricing under the Inflation Reduction Act effective 2026.
- 340B & Insulin Litigation: Ongoing legal challenges regarding 340B program interpretations and insulin pricing. A recent appellate court decision reversed a dismissal in a 340B antitrust case, remanding it for further proceedings.
- Acquisitions: Acquired Verve Therapeutics (cardiovascular gene editing) in July 2025 for approx. $549M cash plus contingent value rights. Acquired Scorpion Therapeutics' PI3Kα inhibitor program in March 2025.
- Shareholder Returns: Repurchased $2.60 billion of shares in the first nine months of 2025 under a $15 billion program ($12.40 billion remaining). Declared Q4 2025 dividend of $1.50 per share.
Investor Verification Checklist
- Supply Chain Status: Verify the sustainability of the "supply exceeds demand" claim for tirzepatide and monitor for potential future shortages or production delays.
- Regulatory Pricing Impact: Assess the financial impact of the Inflation Reduction Act price negotiations on Jardiance starting in 2026 and potential future selections of Mounjaro/Zepbound.
- Acquisition Integration: Monitor the progress and milestone achievements of the Verve Therapeutics acquisition (VERVE-102) and the commercialization of the Scorpion Therapeutics asset (STX-478).
- Legal Exposure: Track the status of the 340B antitrust litigation (Mosaic Health) and the Actos bladder cancer litigation, as adverse outcomes could result in material charges.
- Tax Rate Volatility: Review the long-term impact of the OBBBA on the effective tax rate, noting the Q3 2025 charge was a one-time remeasurement.